相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
S. A. Quezada et al.
BRITISH JOURNAL OF CANCER (2013)
Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Caroline J. Breitbach et al.
CANCER RESEARCH (2013)
Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment-Poor Prognosis or New Therapeutic Opportunity
Lisa A. Ridnour et al.
CLINICAL CANCER RESEARCH (2013)
Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses
K-W Peng et al.
GENE THERAPY (2013)
The Efficacy Versus Toxicity Profile of Combination Virotherapy and TLR Immunotherapy Highlights the Danger of Administering TLR Agonists to Oncolytic Virus-treated Mice
Diana M. Rommelfanger et al.
MOLECULAR THERAPY (2013)
HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy
Byram W. Bridle et al.
MOLECULAR THERAPY (2013)
Functional Cloning of Recurrence-specific Antigens Identifies Molecular Targets to Treat Tumor Relapse
Nicolas Boisgerault et al.
MOLECULAR THERAPY (2013)
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo et al.
NATURE MEDICINE (2013)
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Caroline J. Voskens et al.
PLOS ONE (2013)
Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy
Leonard Armstrong et al.
AMERICAN JOURNAL OF SURGERY (2012)
Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β
S. Naik et al.
CANCER GENE THERAPY (2012)
Increasing the efficacy of tumor cell vaccines by enhancing cross priming
Brian M. Andersen et al.
CANCER LETTERS (2012)
Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus
Iulia Diaconu et al.
CANCER RESEARCH (2012)
Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
Sari Pesonen et al.
CANCER RESEARCH (2012)
Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective
Dung T. Le et al.
CANCER RESEARCH (2012)
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4
J. D. Dias et al.
GENE THERAPY (2012)
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors
Sari Pesonen et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Enhanced antitumoral efficacy and immune response following conditionally replicative adenovirus containing constitutive HSF1 delivery to rodent tumors
Rong Fan et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer
James M. Burke et al.
JOURNAL OF UROLOGY (2012)
The Histone Deacetylase Inhibitor Valproic Acid Lessens NK Cell Action against Oncolytic Virus-Infected Glioblastoma Cells by Inhibition of STAT5/T-BET Signaling and Generation of Gamma Interferon
Christopher A. Alvarez-Breckenridge et al.
JOURNAL OF VIROLOGY (2012)
Curative one-shot systemic virotherapy in murine myeloma
S. Naik et al.
LEUKEMIA (2012)
Treating Tumors With a Vaccinia Virus Expressing IFNβ Illustrates the Complex Relationships Between Oncolytic Ability and Immunogenicity
Liang-Chuan S. Wang et al.
MOLECULAR THERAPY (2012)
An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor Clearance
Vincenzo Cerullo et al.
MOLECULAR THERAPY (2012)
The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers
Kelley A. Parato et al.
MOLECULAR THERAPY (2012)
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma
Jose Pulido et al.
NATURE BIOTECHNOLOGY (2012)
Oncolytic virotherapy
Stephen J. Russell et al.
NATURE BIOTECHNOLOGY (2012)
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors
Christopher A. Alvarez-Breckenridge et al.
NATURE MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines
Ravi A. Madan et al.
SEMINARS IN ONCOLOGY (2012)
Delivery of interferon alpha using a novel Cox2-controlled adenovirus for pancreatic cancer therapy
Leonard Armstrong et al.
SURGERY (2012)
Recombinant viral vaccines for cancer
Ryan Cawood et al.
TRENDS IN MOLECULAR MEDICINE (2012)
Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer
Svitlana P. Grekova et al.
CANCER BIOLOGY & THERAPY (2011)
Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
Wilfred D. Stein et al.
CLINICAL CANCER RESEARCH (2011)
Idiotype vaccines for lymphoma therapy
Susana Inoges et al.
EXPERT REVIEW OF VACCINES (2011)
Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come
Ayesha Murshid et al.
EXPERT REVIEW OF VACCINES (2011)
CpG DNA as a vaccine adjuvant
Christian Bode et al.
EXPERT REVIEW OF VACCINES (2011)
Myeloma Xenograft Destruction by a Nonviral Vector Delivering Oncolytic Infectious Nucleic Acid
Elizabeth M. Hadac et al.
MOLECULAR THERAPY (2011)
VSV Oncolytic Virotherapy in the B16 Model Depends Upon Intact MyD88 Signaling
Phonphimon Wongthida et al.
MOLECULAR THERAPY (2011)
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy
Jeong Heo et al.
MOLECULAR THERAPY (2011)
Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
Vincenzo Cerullo et al.
MOLECULAR THERAPY (2011)
Oncolytic Virus-initiated Protective Immunity Against Prostate Cancer
Shashi A. Gujar et al.
MOLECULAR THERAPY (2011)
Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy
Paul T. Sobol et al.
MOLECULAR THERAPY (2011)
A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
Tae-Ho Hwang et al.
MOLECULAR THERAPY (2011)
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Caroline J. Breitbach et al.
NATURE (2011)
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors
Timothy Kottke et al.
NATURE MEDICINE (2011)
Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis
Andreas Draube et al.
PLOS ONE (2011)
Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine
Basav N. Hangalapura et al.
VACCINE (2011)
Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
Howard L. Kaufman et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Type III IFN Interleukin-28 Mediates the Antitumor Efficacy of Oncolytic Virus VSV in Immune-Competent Mouse Models of Cancer
Phonphimon Wongthida et al.
CANCER RESEARCH (2010)
The Current and Emerging Role of Immunotherapy in Prostate Cancer
Ravi A. Madan et al.
CLINICAL GENITOURINARY CANCER (2010)
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
Howard L. Kaufman et al.
FUTURE ONCOLOGY (2010)
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma
F. Galivo et al.
GENE THERAPY (2010)
Evaluation of an Attenuated Vesicular Stomatitis Virus Vector Expressing Interferon-beta for Use in Malignant Pleural Mesothelioma: Heterogeneity in Interferon Responsiveness Defines Potential Efficacy
Vassiliki Saloura et al.
HUMAN GENE THERAPY (2010)
Safety Studies on Intrahepatic or Intratumoral Injection of Oncolytic Vesicular Stomatitis Virus Expressing Interferon-β in Rodents and Nonhuman Primates
Nathan Jenks et al.
HUMAN GENE THERAPY (2010)
Interference of CD40L-Mediated Tumor Immunotherapy by Oncolytic Vesicular Stomatitis Virus
Feorillo Galivo et al.
HUMAN GENE THERAPY (2010)
Enhancement of dendritic cells as vaccines for cancer
Meghan E. Turnis et al.
IMMUNOTHERAPY (2010)
Low-dose Cyclophosphamide Treatment Impairs Regulatory T Cells and Unmasks AFP-specific CD4+ T-cell Responses in Patients With Advanced HCC
Tim F. Greten et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Improved Endpoints for Cancer Immunotherapy Trials
Axel Hoos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
HSF1 overexpression enhances oncolytic effect of replicative adenovirus
Cheng Wang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity
Shashi A. Gujar et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Selectivity of Oncolytic Viral Replication Prevents Antiviral Immune Response and Toxicity, but Does Not Improve Antitumoral Immunity
Engin Guerlevik et al.
MOLECULAR THERAPY (2010)
Potentiating Cancer Immunotherapy Using an Oncolytic Virus
Byram W. Bridle et al.
MOLECULAR THERAPY (2010)
Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF
Anniina Koski et al.
MOLECULAR THERAPY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression
Ravi A. Madan et al.
ONCOLOGIST (2010)
A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients
J-L Li et al.
GENE THERAPY (2009)
Dendritic cells from bench to bedside and back
G. J. Adema
IMMUNOLOGY LETTERS (2009)
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
Neil N. Senzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Enhancement of Oncolytic Properties of Recombinant Newcastle Disease Virus Through Antagonism of Cellular Innate Immune Responses
Dmitriy Zamarin et al.
MOLECULAR THERAPY (2009)
Vesicular Stomatitis Virus as a Novel Cancer Vaccine Vector to Prime Antitumor Immunity Amenable to Rapid Boosting With Adenovirus
Byram W. Bridle et al.
MOLECULAR THERAPY (2009)
In situ adenovirus vaccination engages T effector cells against cancer
Sebastian Tuve et al.
VACCINE (2009)
Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity
Robin J. Prestwich et al.
CLINICAL CANCER RESEARCH (2008)
Heat-shock protein-based vaccines for cancer and infectious disease
Robert J. Binder
EXPERT REVIEW OF VACCINES (2008)
Heat shock protein inhibitors increase the efficacy of measles virotherapy
C. Liu et al.
GENE THERAPY (2008)
Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity
Zahari Raykov et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
An adjuvant autologous therapeutic vaccine (HSPPC-96 vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentrel, open-label, randomised phase III trial
Christopher Wood et al.
LANCET (2008)
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Byeong-Ho Park et al.
LANCET ONCOLOGY (2008)
The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma
Ta-Chiang Liu et al.
MOLECULAR THERAPY (2008)
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis
Thi Lien-Anh Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
How dying cells alert the immune system to danger
Hajime Kono et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide
R. M. Myers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus
David H. Kirn et al.
PLOS MEDICINE (2007)
Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling
Henriette Bendz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus
Rosa Maria Diaz et al.
CANCER RESEARCH (2007)
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C. C. Hu et al.
CLINICAL CANCER RESEARCH (2006)
Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model
Young-Sook Lee et al.
CLINICAL CANCER RESEARCH (2006)
Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF
J. H. Kim et al.
MOLECULAR THERAPY (2006)
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
Giulia Fulci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect
K-J Choi et al.
GENE THERAPY (2006)
Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-γ gene yields efficient antitumor activity in immunodeficient and immunocompetent mice
Changqing Su et al.
MOLECULAR THERAPY (2006)
Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy
Y Ino et al.
CLINICAL CANCER RESEARCH (2006)
CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer
N Ramesh et al.
CLINICAL CANCER RESEARCH (2006)
Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system
H Fukuhara et al.
CANCER RESEARCH (2005)
Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy
CC O'Shea et al.
CANCER CELL (2005)
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
MEC Lutsiak et al.
BLOOD (2005)
Heat shock protein 72 expression allows permissive replication of oncolytic adenovirus dl1520 (ONYX-015) in rat glioblastoma cells
Jonathan Madara et al.
MOLECULAR CANCER (2005)
Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles
M Bereta et al.
CANCER GENE THERAPY (2004)
Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells
H Wakimoto et al.
GENE THERAPY (2003)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
Danger signals: SOS to the immune system
S Gallucci et al.
CURRENT OPINION IN IMMUNOLOGY (2001)
Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
B Sauter et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
